J&J’s One-Shot Vaccine Shows 66% Efficacy, But Company Says There’s More To It

Prevention Of Severe Disease Consistent Across Geographies

The drug maker played up the 85% prevention of severe disease and 100% prevention of hospitalization and death despite lower overall efficacy relative to mRNA vaccines.

COVID-19 vaccine
J&J says there's more to its COVID-19 vaccine efficacy numbers than meets the eye. • Source: Shutterstock

Johnson & Johnson reported a significantly lower overall efficacy figure in interim data from the first Phase III trial of its single-dose vaccine against SARS-CoV-2 than those of competitors, causing widespread disappointment and concerns about its efficacy, particularly in the context of worries about a South African variant of the virus that has arrived in the US. But the company has suggested there is more than meets the eye.

The New Brunswick, NJ-based drug maker reported on 29 January data from the Phase III ENSEMBLE trial of JNJ-78436735, also...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By 

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip